Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

NCT02188160 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye Syndromes
Keratoconjunctivitis Sicca

Interventions

DRUG: KPI-121
DRUG: Placebo

Sponsor

Kala Pharmaceuticals, Inc.